Rethinking Schizophrenia Disclaimer

Boehringer Ingelheim were in regular communication with, and provided data upon request to Rethink Mental Illness, in addition to attending a number of engagement sessions in an observational capacity. Rethink Mental Illness have editorial control of all content, which has been reviewed by Boehringer in line with the ABPI (Association of British Pharmaceutical Industry) Code of Practice. The independence of Rethink Mental Illness has been maintained. 

The opinions and accounts expressed by patients and Rethink Mental Illness in this report are their own and do not necessarily reflect the views, policies or positions of Boehringer Ingelheim. These testimonials are included solely to share individual lived experiences and should not be interpreted as official Boehringer Ingelheim statements. 

The report contains quotes of people’s experience with medications. Licensed medications have demonstrated benefits for appropriate patients, as well as having side effects. It is important that these are communicated and monitored by healthcare professionals (HCPs). The decision to use a particular medication should be made by a HCP, along with the patient and/or carer.